Sucampo and Takeda’s Amitiza Approved for IBS-c

On a disease sexiness scale from 0-100, chronic idiopathic constipation (CIC) and irritable bowel syndrome (IBS-c) are close to rounding out the bottom of that range however, they remain important medical problems. CIC accounts for roughly 6 million related outpatient visits each year and just over a quarter million hospital admissions with constipation as [...]